Platelet Recovery Before Allogeneic Stem Cell Transplantation Predicts Posttransplantation Outcomes in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome

被引：17

作者：

Alatrash, Gheath ^{[1
]}

Pelosini, Matteo ^{[1
]}

Saliba, Rima M. ^{[1
]}

Koca, Ebru ^{[1
]}

Rondon, Gabriela ^{[1
]}

Andersson, Borje S. ^{[1
]}

Chiattone, Alexandre ^{[1
]}

Zhang, Weiqing ^{[1
]}

Giralt, Sergio A. ^{[1
]}

Cernosek, Amanda M. ^{[1
]}

Kebriaei, Partow ^{[1
]}

Alousi, Amin M. ^{[1
]}

Popat, Uday R. ^{[1
]}

Hosing, Chitra ^{[1
]}

Khouri, Issa F. ^{[1
]}

Champlin, Richard E. ^{[1
]}

de Lima, Marcos J. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Unit 423, Houston, TX 77030 USA

来源：

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2011年 / 17卷 / 12期

关键词：

CRp; Platelet recovery; AML; MDS; Transplant; ACUTE MYELOID-LEUKEMIA; GEMTUZUMAB OZOGAMICIN; EFFICACY; RELAPSE; SAFETY;

D O I：

10.1016/j.bbmt.2011.05.018

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Complete remission (CR) is the gold standard for assessing outcomes following chemotherapy for acute myelogenous leukemia (AML). "CRp," a response criterion defined as fulfillment of all criteria for CR except platelet count recovery to >= 100 x 10(9)/L, is associated with inferior outcomes following chemotherapy. The prognostic importance of CRp before allogeneic stem cell transplantation (allo-SCT) remains unknown. We analyzed a cohort of AML (n = 334) and myelodysplastic syndrome (MDS; n = 10) patients to determine the prognostic significance of achieving CR versus CRp before allo-SCT. At time of transplantation, 266 patients were in CR (CRI and >= CR2) and 78 in CRp (CRI p and >= CR2p). Median follow-up was 38 months (3-131 months). Overall survival, progression-free survival, and nonrelapse mortality (NRM) were most favorable in patients transplanted in CR (CRI or >= CR2) compared with CRp (CRI p or >= CR2p). Achieving CR is therefore associated with improved posttransplantation outcomes compared with achieving CRp and is a significant prognostic factor that needs to be considered when evaluating AMLJMDS patients for clinical trials and allo-SCT. Biol Blood Marrow Transplant 17: 1841-1845 (2011) (C) 2011 American Society fir Blood and Marrow Transplantation

引用

页码：1841 / 1845

页数：5

共 13 条

[1] Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia:: results from Cancer and Leukemia Group B (CALGB 8461) [J].

Byrd, JC ;

Mrózek, K ;

Dodge, RK ;

Carroll, AJ ;

Edwards, CG ;

Arthur, DC ;

Pettenati, MJ ;

Patil, SR ;

Rao, KW ;

Watson, MS ;

Koduru, PRK ;

Moore, JO ;

Stone, RM ;

Mayer, RJ ;

Feldman, EJ ;

Davey, FR ;

Schiffer, CA ;

Larson, RA ;

Bloomfield, CD .

BLOOD, 2002, 100 (13) :4325-4336

[2] Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia [J].

Cheson, BD ;

Bennett, JM ;

Kopecky, KJ ;

Büchner, T ;

Willman, CL ;

Estey, EH ;

Schiffer, CA ;

Döhner, H ;

Tallman, MS ;

Lister, TA ;

LoCocco, F ;

Willemze, R ;

Biondi, A ;

Hiddemann, W ;

Larson, RA ;

Löwenberg, B ;

Sanz, MA ;

Head, DR ;

Ohno, R ;

Bloomfield, CD .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) :4642-4649

[3]

ESTEY E, 2005, BLOOD, V106

[4]

Etienne A, 2008, BLOOD

[5] Low-Dose Azacitidine After Allogeneic Stem Cell Transplantation for Acute Leukemia [J].

Jabbour, Elias ;

Giralt, Sergio ;

Kantarjian, Hagop ;

Garcia-Manero, Guillermo ;

Jagasia, Madan ;

Kebriaei, Partow ;

de Padua, Leandro ;

Shpall, Elizabeth J. ;

Champlin, Richard ;

de Lima, Marcos .

CANCER, 2009, 115 (09) :1899-1905

[6] NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].

KAPLAN, EL ;

MEIER, P .

JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481

[7]

KEATING MJ, 1980, CANCER-AM CANCER SOC, V45, P2017, DOI 10.1002/1097-0142(19800415)45:8<2017::AID-CNCR2820450806>3.0.CO

[8]

2-C

[9] Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence [J].

Larson, RA ;

Sievers, EL ;

Stadtmauer, EA ;

Löwenberg, B ;

Estey, EH ;

Dombret, H ;

Theobald, M ;

Voliotis, D ;

Bennett, JM ;

Richie, M ;

Leopold, LH ;

Berger, MS ;

Sherman, ML ;

Loken, MR ;

van Dongen, JJM ;

Bernstein, ID ;

Appelbaum, FR .

CANCER, 2005, 104 (07) :1442-1452

[10] Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML [J].

Nevill, T. J. ;

Hogge, D. E. ;

Toze, C. L. ;

Nantel, S. H. ;

Power, M. M. ;

Abou Mourad, Y. R. ;

Song, K. W. ;

Lavoie, J. C. ;

Forrest, D. L. ;

Barnett, M. J. ;

Shepherd, J. D. ;

Nitta, J. Y. ;

Wong, S. ;

Sutherland, H. J. ;

Smith, C. A. .

BONE MARROW TRANSPLANTATION, 2008, 42 (10) :659-666

← 1 2 →